Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 54

recruiting
3 987
countries
28
conditions
2 109

988 trials match your criteria

Hodgkin's disease

Not recruiting

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin

Haematological malignancy+1

Not recruiting

Study of Elraglusib Alone or with Chemotherapy for Patients with Refractory Blood Cancers or Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elraglusib

Desmoid tumour

Not recruiting

Study of varegacestat (AL102) in patients with progressing desmoid tumors

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Varegacestat

Endometrial cancer recurrent

Not recruiting

Study on Durvalumab, Olaparib, and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer in Spain

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Hormone receptor positive breast cancer+1

Not recruiting

Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Neratinib

Fabry's disease

Not recruiting

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lucerastat

Breast cancer

Not recruiting

Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study of Rituximab, Gemcitabine, Dexamethasone, and Platinum with or without Selinexor for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Malignant melanoma

Not recruiting

Study on Tebentafusp and Drug Combination for Patients with Advanced Uveal Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine

Amyotrophic lateral sclerosis

Not recruiting

Study of Lithium Treatment for Patients with Amyotrophic Lateral Sclerosis (ALS) to Evaluate Survival Rate

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Letrozole

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.